Clinical and investigational use of proteasome inhibitors for transplant rejection

Bibliography

• Mao Q, Terasaki PI, Cai J, Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007;7:864-71
   PubMed Web of Science ®Google Scholar
• Lee PC, Zhu L, Terasaki PI, HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009;88:568-74
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Arend LJ, Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009;9:1063-71
   PubMed Web of Science ®Google Scholar
• Ramos EJ, Pollinger HS, Stegall MD, The effect of desensitization protocols on human splenic B-cell populations in-vivo. Am J Transplant 2007;7:402-7
   PubMed Web of Science ®Google Scholar
• Perry DK, Burns JM, Pollinger HS, Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009;9:201-9
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Susskind B, Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008;86:1754-61
   PubMed Web of Science ®Google Scholar
• Walsh RC, Everly JJ, Brailey P, Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010;89:277-84
   PubMed Web of Science ®Google Scholar
• Everly JJ, Walsh RC, Alloway RR, Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009;14(6):662-6
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003;29:3-9
   PubMed Web of Science ®Google Scholar
• Wu Y. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant 2002;2:904-12
   PubMed Web of Science ®Google Scholar
• DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999;274:22123-6
   PubMed Web of Science ®Google Scholar
• Groll M, Koguchi Y, Huber R, Crystal structure of the 20S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001;311(3):543-8
   PubMed Web of Science ®Google Scholar
• Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004;16:76-81
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, Role of the unfolded protein response in cell death. Apoptosis 2006;11:5-13
   PubMed Web of Science ®Google Scholar
• Gomez AM, Vrolix K, Martinez-Martinez P, Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 2011;186:2503-13
   PubMed Web of Science ®Google Scholar
• Cascio P, Oliva L, Cerruti F, Damping Ab responses using proteasome inhibitors following in-vivo B cell activation. Eur J Immunol 2008;38:658-67
   PubMed Web of Science ®Google Scholar
• Cenci S, Mezghrani A, Cascio P, Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J 2006;25:1104-13
   PubMed Web of Science ®Google Scholar
• Bianchi G, Oliva L, Cascio P, The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009;113(13):3040-9
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DM, Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16
   PubMed Web of Science ®Google Scholar
• Neubert K, Meister K, Moser F, The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008;14:748-55
   PubMed Web of Science ®Google Scholar
• Luo H, Wu Y, Qi S, A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001;72:196-202
   PubMed Web of Science ®Google Scholar
• Wu Y, Han B, Luo H, Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection. Transplantation 2004;78:360-6
   PubMed Web of Science ®Google Scholar
• Basadonna GP, Matas AJ, Gillingham KJ, Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993;55:993-5
   PubMed Web of Science ®Google Scholar
• Sipkens YW, Doxidis II, Mallat MJK, Early versus late acute rejection episodes in renal transplantation. Transplantation 2004;75:204-8
   Web of Science ®Google Scholar
• Walsh RC, Brailey P, Girnita A, Early and late acute antibody-mediated rejection differs immunologically and in response to proteasome inhibition. Transplantation 2011;91(11):1218-26
   PubMed Web of Science ®Google Scholar
• Flechner SM, Fatica R, Askar M, The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010;90:1486-92
   PubMed Web of Science ®Google Scholar
• Woodle ES, Light J, Franklin C, A multicenter, prospective, collaborative evaluation of proteasome inhibition for the treatment of antibody mediated rejection in solid organ transplantation. [abstract #428]. Am J Transplant 2011;10(s4):159
   Google Scholar
• Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010;10:681-6
   PubMed Web of Science ®Google Scholar
• Everly MJ. A summary of bortezomib use in transplantation across 29 centers. Clin Transpl 2010;323-37
   PubMedGoogle Scholar
• Cooper JE, Wiseman AC, Chan L. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases. Clin Transpl 2010;455-9
   Google Scholar
• Wong W, Lee RA, Saidman SL, Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports. Clin Transpl 2010;401-5
   Google Scholar
• Raghavan R, Jeroudi A, Achkar K, Bortezomib in kidney transplant desensitization: a case report. Clin Transpl 2010;339-42
   Google Scholar
• Govil A, Walsh RC, Tevar A, Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients. Clin Transpl 2010;443-53
   Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. NEJM 2005;352(24):2487-98
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25(25):3892-901
   PubMed Web of Science ®Google Scholar
• Schmidt N, Alloway RR, Sadaka B, Intermediate-term global toxicity analysis of proteasome inhibitor-based antihumoral therapy. [abstract #192]. Am J Transplant 2011;11(s2):192
   Google Scholar
• Ashton-Chess J, Mai HL, Jovanovic V, Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection. Kidney Int 2010;77:880-90
   PubMed Web of Science ®Google Scholar
• Raghavaiah SR, Diwan TS, Burns JM, Depletion of alloantibody-secreting plasma cells by proteasome inhibition improves desensitization. [abstract #22]. Am J Transplant 2010;10(s4):44-5
   Google Scholar
• Wahrmann M, Haidinger M, Kormoczi GF, Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010;89:1385-90
   PubMed Web of Science ®Google Scholar
• Diwan TS, Raghavaiah S, Burns JM, The impact of proteasome inhibition on alloantibody-producing plasma cells in-vivo. Transplantation 2011;91:536-41
   PubMed Web of Science ®Google Scholar
• Walsh RC, Shields AR, Girnita A, A prospective, staged trial of proteasome inhibitor-based therapy for reduction of HLA sensitization in kidney transplant candidates. Am J Transplant 2011; [submitted]
   Web of Science ®Google Scholar
• Potts BC, Albitar MX, Anderson KC, Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework. Curr Cancer Drug Targets 2011;11(3):254-84
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 2011;11(3):285-95
   PubMed Web of Science ®Google Scholar